Beta-blockers reduce bone resorption marker in early postmenopausal women.

Abstract

BACKGROUND: There is evidence to suggest that beta-blockers used in the management of cardiovascular disease may also modulate bone metabolism and reduce bone fragility. AIM: The study aimed to determine the association between beta-blocker use, serum markers of bone turnover and bone loss in early postmenopausal women. SUBJECTS AND METHODS: In this observational study, we evaluated beta-blocker exposure in association with serum levels of C-telopeptide and bone-specific alkaline phosphatase, and rates of bone loss. Beta-blocker use, concomitant therapy and lifestyle were documented for 197 women (50-59 years), 175 of whom had changes in whole body bone mineral density monitored over a 2-yea..